Imugene Limited (ASX:IMU) specialises in the development of animal health products for pigs and poultry, including vaccines and productivity enhancers.
These biologically-based vaccines:
- Improve the health and welfare of pigs and poultry
- Reduce or eliminate the use of antibiotics, chemicals and drugs, and;
- Result in economic gains for the industries that use them.
Imugene's product portfolio targets a worldwide US$3 billion animal health market and contains vaccines at each stage of the development process.
Constructed using Imugene’s patented Porcine and Fowl Adenoviral Vector Delivery Systems, these vaccines address some of the major diseases and health issues threatening pig and poultry production worldwide, such as Porcine Reproductive and Respiratory Syndrome (PRRS), which causes losses of up to US$1 billion every year.
Together with its Poultry Productivity Enhancer (PPE), the PRRS vaccine is Imugene’s most advanced product.
Among Imugene’s other products are vaccines targeting the H1N1 and H3N2 swine flu strains and the H7 and H9 avian influenza strains.
Learn more about Imugene’s products and technology.